Insights into the mechanisms of action of chloroquine and hydroxychloroquine and its use in COVID-19 for chemoprophylaxis

M. Sahu, Arvind Kumar, S. Shankar, Diksha Patidar, V. Vishwakarma, P. Sahoo, N. Wig
{"title":"Insights into the mechanisms of action of chloroquine and hydroxychloroquine and its use in COVID-19 for chemoprophylaxis","authors":"M. Sahu, Arvind Kumar, S. Shankar, Diksha Patidar, V. Vishwakarma, P. Sahoo, N. Wig","doi":"10.22541/au.158981181.19035548","DOIUrl":null,"url":null,"abstract":"The global outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) has put forth a serious threat to international public health and has ruined the global economy. Till date, no drugs have been approved for coronavirus disease-2019 (COVID-19), although the use of some drugs in the trial phase has been attempted. The drugs being used for the management of COVID-19 disease include chloroquine (CQ), hydroxychloroquine (HCQ), and remdesivir. In this article, we have aimed to review existing literature and mechanism by which CQ and HCQ have an effect on COVID-19, most importantly by interfering with autophagy, lysosomal activity, receptor binding, and membrane fusion. We have systematically searched the PubMed database up to April 2020 and analyzed all the articles published on CQ, HCQ, and COVID-19. The available data provide insights into the immunomodulatory potency of HCQ, along with the molecular mechanism of action of the drug on the SARS-CoV-2.","PeriodicalId":93784,"journal":{"name":"Journal of primary care specialties : official publication of the Institute of Family Medicine and Primary Care","volume":"163 1","pages":"27 - 32"},"PeriodicalIF":0.0000,"publicationDate":"2020-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of primary care specialties : official publication of the Institute of Family Medicine and Primary Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22541/au.158981181.19035548","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The global outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) has put forth a serious threat to international public health and has ruined the global economy. Till date, no drugs have been approved for coronavirus disease-2019 (COVID-19), although the use of some drugs in the trial phase has been attempted. The drugs being used for the management of COVID-19 disease include chloroquine (CQ), hydroxychloroquine (HCQ), and remdesivir. In this article, we have aimed to review existing literature and mechanism by which CQ and HCQ have an effect on COVID-19, most importantly by interfering with autophagy, lysosomal activity, receptor binding, and membrane fusion. We have systematically searched the PubMed database up to April 2020 and analyzed all the articles published on CQ, HCQ, and COVID-19. The available data provide insights into the immunomodulatory potency of HCQ, along with the molecular mechanism of action of the drug on the SARS-CoV-2.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氯喹和羟氯喹的作用机制及其在COVID-19化学预防中的应用
由严重急性呼吸系统综合征(SARS-CoV-2/2019-nCoV)引起的2019冠状病毒病(COVID-19)在全球爆发,对国际公共卫生构成严重威胁,对全球经济造成严重破坏。到目前为止,还没有药物被批准用于治疗冠状病毒病-2019 (COVID-19),尽管已经尝试在试验阶段使用一些药物。目前用于治疗COVID-19疾病的药物包括氯喹(CQ)、羟氯喹(HCQ)和瑞德西韦。在本文中,我们旨在回顾CQ和HCQ对COVID-19的影响的现有文献和机制,主要是通过干扰自噬、溶酶体活性、受体结合和膜融合。我们系统检索了截至2020年4月的PubMed数据库,分析了所有关于CQ、HCQ和COVID-19的发表文章。现有数据为HCQ的免疫调节效力以及药物对SARS-CoV-2的作用分子机制提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Cutaneous adverse drug reactions in a tertiary care setup: A cross-sectional observational single-center-based study in Eastern India Knowledge and perceptions of medical students about generic medicines in a medical college in North India Acute undifferentiated fever presenting as multi-organ dysfunction: Narrowing the differential diagnosis A study on patients with pleural effusion with emphasis on pleural fluid adenosine deaminase and pleural biopsy Corticosteroid-induced avascular bone necrosis and possible association with prior COVID-19 infection
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1